Janpraz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide effective management of gastrointestinal disorders. Pantoprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, while also providing antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone. This synergistic combination is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and symptomatic relief of nausea and vomiting associated with delayed gastric emptying. Janpraz-DSR is particularly beneficial in patients requiring both acid suppression and prokinetic action for optimal symptom control. The capsule should be administered as prescribed by a healthcare professional, typically before meals to maximize therapeutic efficacy. Caution is advised in patients with known hypersensitivity to either component, and it should be used with care in individuals with hepatic or renal impairment. Adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. Regular monitoring and adherence to prescribed dosage are essential for safe and effective treatment outcomes.